Jeffrey Elliott serves as the Executive Vice President and Chief Financial Officer at EXACT SCIENCES CORP, a leading molecular diagnostics company focused on the early detection and prevention of cancer. In his role, Elliott oversees the company's financial strategy, planning, and operations, playing a crucial role in driving EXACT SCIENCES' growth and success. With his extensive experience in finance and leadership, he has been instrumental in guiding the company through significant milestones, including the successful launch and expansion of their flagship product, Cologuard, a non-invasive stool-based DNA test for colorectal cancer screening. Prior to joining EXACT SCIENCES in 2016, Elliott held several high-level financial positions at notable healthcare and life sciences companies. He spent nearly a decade at Invensys, a global industrial software and automation company, where he served as the Chief Financial Officer for their Performance Solutions division. Before that, he was the Vice President of Finance at Hologic, a medical technology company specializing in women's health. Elliott's strong financial acumen and strategic vision have been key factors in his ability to navigate complex financial landscapes and drive sustainable growth for the organizations he has served. Under Elliott's leadership, EXACT SCIENCES has experienced significant financial growth and stability, positioning the company as a leader in the molecular diagnostics industry. His expertise in financial planning, investor relations, and mergers and acquisitions has been vital in securing the resources needed to advance the company's mission of improving patient outcomes through early cancer detection. Elliott's dedication to the company's success and his commitment to advancing healthcare innovation make him an invaluable asset to EXACT SCIENCES and the broader healthcare community.